Antiparasitic Agents Based on mTOR Inhibitors
- Technology Benefits
- The inhibitors:ΓÇóAct as a single therapeutic agent to potentially treat all three major trypanosomatid pathogens(T. brucei, T. cruzi, and Leishmania sp.)ΓÇóShowed micro molar or better efficacy against some of these parasitic organismsΓÇóAre further optimized to improve their selectivityΓÇóAre effective in treating some or all of the people infected with neglected tropical diseasesΓÇóAre further useful for anti-trypanosomal drug discovery
- Detailed Technology Description
- None
- *Abstract
-
Parasitic diseases represent a significant health problem, especially in the developing world. It is estimated that over 22 million people are infected with such diseases annually. Current therapies are associated with limited efficacies, large treatment costs, and life threatening side effects. As a result, such therapies desperately need improvement. This novel approach enables use of mTOR/phosphoinositide-3-kinase (PI3K) inhibitors as effective anti-parasitic agents.
- *Principal Investigator
-
Name: Stephen Beverly
Department:
Name: Miguel Navarro
Department:
Name: Michael Pollastri
Department:
Name: Ana Rodriguez
Department:
- Country/Region
- USA
For more information, please click Here
